Catalyst Pharmaceutical Partners Inc.

Home » Catalyst Pharmaceutical Partners Inc.

Secondary

Catalyst Pharmaceutical Partners Inc.

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, and infantile spasms. Firdapse has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis.

Symbol

CPRX

Last Closing Price
$3.61

Shares
11,000,000

Effective Date
November 28, 2017

Underwriters
Piper Jaffray, SunTrust Robinson

To view the prospectus for Catalyst Pharmaceutical Partners Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253